Oncolytics Biotech Inc.
NCM: ONCYLive Quote
About Oncolytics Biotech Inc.
Healthcare
Biotechnology
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.
📊 Fundamental Analysis
Oncolytics Biotech Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
At a current price of $0.93, ONCY currently sits at the 51st percentile of its 52-week range (Range: $0.33 - $1.51).
🏥 Financial Health
🔴
Profit Margin
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$171.23M
Trailing P/E
--
Forward P/E
-3.93
Beta (5Y)
0.99
52W High
$1.51
52W Low
$0.33
Avg Volume
1.41M
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App